Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772965 | 0.88 | NR3C1 (0.62) | NR3C1 | |
| SCHEMBL12956484 | 0.88 | NR3C1 (0.65) | NR3C1 | |
| SCHEMBL30969257 | 0.87 | KDM4E (0.62) | NR3C1 | |
| SCHEMBL5717703 | 0.87 | KDM4E (0.62) | NR3C1 | |
| SCHEMBL17963084 | 0.86 | NR3C1 (0.62) | NR3C1 | |
| SCHEMBL12391735 | 0.84 | NR3C1 (0.58) | NR3C1 | |
| SCHEMBL17963412 | 0.84 | NR3C1 (0.64) | NR3C1 | |
| SCHEMBL17963111 | 0.84 | NR3C1 (0.64) | NR3C1 | |
| SCHEMBL14958570 | 0.83 | PDE4A (0.51) | NR3C1 | |
| SCHEMBL583418 | 0.82 | KMT2A (0.75) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4829451-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-6599918-B2 | Inhibit Factor Xa Factor IIa (thrombin) | AVENTIS PHARMACEUTICALS INC. | 2003-07-29 | — | — | US | claimed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | claimed |
| EP-1222182-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | Aventis Pharmaceuticals Inc. (US) | 2002-07-17 | — | — | EP | claimed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | claimed |
| US-10711027-B2 | DNA polymerase beta inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-07-04 | — | — | US | disclosed |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| WO-2016123392-A2 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1222182-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | Aventis Pharmaceuticals Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION | 2001-11-29 | — | — | US | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | NR3C1, NR3C2, GRK3 | NR3C1 1/4885 |
| US-10711027-B2 | DNA polymerase beta inhibitors | POLB, POLH, POLN | NR3C1 3311/4885 |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | POLB, POLH, POLN | NR3C1 3311/4885 |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | NR3C1, NR3C2, GRK3 | NR3C1 1/4885 |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | F2, TFPI, F3 | NR3C1 4855/4885 |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MSR1, TIMP3, TGFBR2 | NR3C1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.